Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341843 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL10494263 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL2807590 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL4957790 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL31170917 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30198622 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30797948 | 0.91 | GNPAT (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL29374714 | 0.90 | BACE1 (0.48) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30408803 | 0.88 | PTPN1 (0.45) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30317542 | 0.88 | BACE1 (0.43) | LTA4HMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743479-A1 | ADENOVIRUSES | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| EP-4743101-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025012637-A1 | ADENOVIRUSES | THEOLYTICS LTD (GB) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012636-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | THEOLYTICS LTD (GB) | 2025-01-16 | — | — | WO | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| CN-114437207-A | Humanized anti-Hantavirus (HTNV) Fab antibody with neutralization activity and application | 中国人民解放军空军军医大学 | 2022-05-06 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| CN-122103252-A | Umami peptide derived from apostichopus japonicus and preparation method, identification method and application thereof | — | 2026-05-29 | — | — | CN | disclosed |
| US-20260144885-A1 | ANTI-LRRC15 ANTIBODIES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144884-A1 | ANTI-LRRC15 ANTIBODY DRUG CONJUGATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748446-A2 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-4804782-A | ARTIFICIAL SWEETENER | PFIZER, INC. (US) | 1989-02-14 | — | — | US | disclosed |
| US-4797298-A | ARTIFICIAL SWEETENERS FOR BEVERAGES | PFIZER, INC. (US) | 1989-01-10 | — | — | US | disclosed |
| US-4761495-A | Method relating to preparation of aspartyl peptides | ISOCHEM S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| US-4508740-A | Tabletted beverage composition containing dipeptide sweetener and process therefore | GENERAL FOODS CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
| US-4277464-A | ANTICARIES AGENTS | GENERAL FOODS CORPORATION (US) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144884-A1 | ANTI-LRRC15 ANTIBODY DRUG CONJUGATES | VSIG8, IGSF11, SDC1 | LTA4H 3602/4885MME 2950/4885ACE 4604/4885 |
| US-20260144885-A1 | ANTI-LRRC15 ANTIBODIES AND USES THEREOF | IGSF11, VSIG8, BCR | LTA4H 2412/4885MME 3551/4885ACE 4733/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | LTA4H 1194/4885MME 2240/4885ACE 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.